Salient Private Client’s Novo Nordisk NVO Stock Holding History

Salient Private Client’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$501K	Sell	21,236 -1,750	-8%	-$42.7K	0.1%	92
2018 Q2	$530K	Sell	22,986 -100	-0.4%	-$2.38K	0.09%	105
2018 Q1	$568K	Buy	+23,086	New	+$606K	0.1%	101

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

SGA

Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return

Salient Private Client's NVO Position: Q3 2018 in Review

Salient Private Client reduced its Novo Nordisk (NVO) stake by 7.6% in Q3 2018, selling an estimated $42.7K and leaving 21,236 shares worth $501K. The position accounts for 0.1% of the portfolio, ranked #92.

Salient Private Client first reported a position in NVO in Q1 2018 and has held it in 3 quarters since. The position peaked at $568K in Q1 2018. 558 funds tracked by Wall St. Rank hold NVO as of Q3 2018.

Salient Private Client held 21,236 shares of Novo Nordisk worth $501K as of Q3 2018.
Salient Private Client sold 1,750 Novo Nordisk shares in Q3 2018, an estimated $42.7K.
Novo Nordisk made up 0.1% of Salient Private Client's portfolio in Q3 2018, its #92 holding.
Salient Private Client first reported a position in Novo Nordisk in Q1 2018 and has held it in 3 quarters since.
Salient Private Client's Novo Nordisk position peaked at $568K in Q1 2018.
558 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2018.

Based on Salient Private Client's 13F filing for Q3 2018, filed 14 Nov 2018.